Tags

Type your tag names separated by a space and hit enter

Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.
Psychopharmacology (Berl) 2014; 231(10):2211-8P

Abstract

RATIONALE

Metabolic syndrome (MetS) has consistently been identified as an adverse effect of long-term treatment with atypical antipsychotics (AAPs) such as clozapine. Elevated serum homocysteine concentration has been found to act as an independent risk factor for MetS, and catechol-O-methyltransferase (COMT) catalyzes the homocysteine metabolism. We accordingly hypothesized that COMT dysregulation may confer the susceptibility to MetS induced by AAPs, potentially in a gender-specific manner, because the interaction effects of COMT and gender have been consistently reported.

OBJECTIVES

This study aimed at determining the prevalence and influence of COMT on MetS among a population undergoing long-term clozapine treatment.

METHODS

A total of 468 schizophrenia patients taking clozapine were divided into two groups, those experiencing MetS and non-MetS. We genotyped three functional variants (rs4633, rs4680, and rs4818) in COMT and measured the serum levels of fasting homocysteine, glucose, triglyceride (TG), and high-density lipoprotein cholesterol.

RESULTS

MetS was found in 202/468 (43.2 %) of all the patients, with 40.2 % prevalence (138/343) in males and 51.2 % (64/125) in females. Patients with MetS had notably higher metabolic parameters than those without MetS. The mean levels of homocysteine in patients with MetS were significantly higher than those without MetS. We found a positive association between the rs4680 polymorphism and the serum triglyceride levels (corrected P = 0.024). Further analysis revealed that the rs4680 Met allele was significantly associated with increased triglyceride levels among female patients (P = 0.009), but not among males (P = 0.07).

CONCLUSIONS

Our findings suggest a potential association between rs4680 in COMT and elevated TG levels, particularly among female patients.

Authors+Show Affiliations

Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wan Ping Nan Road, Shanghai, 200030, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24448899

Citation

Zhang, Yi, et al. "Metabolic Syndrome in Patients Taking Clozapine: Prevalence and Influence of catechol-O-methyltransferase Genotype." Psychopharmacology, vol. 231, no. 10, 2014, pp. 2211-8.
Zhang Y, Chen M, Chen J, et al. Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Psychopharmacology (Berl). 2014;231(10):2211-8.
Zhang, Y., Chen, M., Chen, J., Wu, Z., Yu, S., Fang, Y., & Zhang, C. (2014). Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Psychopharmacology, 231(10), pp. 2211-8. doi:10.1007/s00213-013-3410-4.
Zhang Y, et al. Metabolic Syndrome in Patients Taking Clozapine: Prevalence and Influence of catechol-O-methyltransferase Genotype. Psychopharmacology (Berl). 2014;231(10):2211-8. PubMed PMID: 24448899.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. AU - Zhang,Yi, AU - Chen,Meijuan, AU - Chen,Jun, AU - Wu,Zhiguo, AU - Yu,Shunying, AU - Fang,Yiru, AU - Zhang,Chen, Y1 - 2014/01/22/ PY - 2013/06/23/received PY - 2013/11/23/accepted PY - 2014/1/23/entrez PY - 2014/1/23/pubmed PY - 2015/2/24/medline SP - 2211 EP - 8 JF - Psychopharmacology JO - Psychopharmacology (Berl.) VL - 231 IS - 10 N2 - RATIONALE: Metabolic syndrome (MetS) has consistently been identified as an adverse effect of long-term treatment with atypical antipsychotics (AAPs) such as clozapine. Elevated serum homocysteine concentration has been found to act as an independent risk factor for MetS, and catechol-O-methyltransferase (COMT) catalyzes the homocysteine metabolism. We accordingly hypothesized that COMT dysregulation may confer the susceptibility to MetS induced by AAPs, potentially in a gender-specific manner, because the interaction effects of COMT and gender have been consistently reported. OBJECTIVES: This study aimed at determining the prevalence and influence of COMT on MetS among a population undergoing long-term clozapine treatment. METHODS: A total of 468 schizophrenia patients taking clozapine were divided into two groups, those experiencing MetS and non-MetS. We genotyped three functional variants (rs4633, rs4680, and rs4818) in COMT and measured the serum levels of fasting homocysteine, glucose, triglyceride (TG), and high-density lipoprotein cholesterol. RESULTS: MetS was found in 202/468 (43.2 %) of all the patients, with 40.2 % prevalence (138/343) in males and 51.2 % (64/125) in females. Patients with MetS had notably higher metabolic parameters than those without MetS. The mean levels of homocysteine in patients with MetS were significantly higher than those without MetS. We found a positive association between the rs4680 polymorphism and the serum triglyceride levels (corrected P = 0.024). Further analysis revealed that the rs4680 Met allele was significantly associated with increased triglyceride levels among female patients (P = 0.009), but not among males (P = 0.07). CONCLUSIONS: Our findings suggest a potential association between rs4680 in COMT and elevated TG levels, particularly among female patients. SN - 1432-2072 UR - https://www.unboundmedicine.com/medline/citation/24448899/Metabolic_syndrome_in_patients_taking_clozapine:_prevalence_and_influence_of_catechol_O_methyltransferase_genotype_ L2 - https://dx.doi.org/10.1007/s00213-013-3410-4 DB - PRIME DP - Unbound Medicine ER -